Pfizer: a new sell signal fires
Pfizer -5.2%: a new sell signal fires, but our model advises against shorting
Our view last week
Pfizer stock slips 1.7% on the week, but the buy signal, now in week 14, is still 7.96% up since entry. The trade is in its management phase and the model's coverage is complete, with all three references already reached. What remains is the residual capital, which our model suggests keeping in the trade.
This week's summary
Pfizer stock falls 5.2% on the week and triggers a new sell signal. Our model sees a decline just getting under way, with lower lows. Opening a short is still not advised: historically, short selling on the signal has lost money on average, because shares tend to rise over time.
Disclaimer. Technical analysis and personal opinion of the author, not financial advice or a personalised recommendation. The author may hold positions in the instruments analysed. Read more ▾Close ▴
Disclaimer — The content on this page is published for educational and informational purposes and represents the author's personal opinion and technical analysis. It is not financial advice, a solicitation to invest, or personalised recommendation. Trading financial instruments involves significant risks and may result in the loss of all or part of the invested capital. Every operational decision is the sole responsibility of the user, who acknowledges acting in full autonomy and full awareness of risk. The author may hold, open or close positions in the instruments analysed, including positions opposite to the analysis, before or after publication, with no obligation to disclose them.
restricted Platinum content